Characterization of hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance

Y Liu, S Chang, R Martin, J Flaherty, H Mo… - Journal of Viral …, 2021 - Wiley Online Library
Both the A194T and a quadruple mutation CYEI (S106C, H126Y, D134E and L269I) in
hepatitis B virus (HBV) polymerase reverse transcriptase domain (pol/RT) are suggested to …

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine

YM Choi, DH Kim, J Jang, BJ Kim - Frontiers in immunology, 2023 - frontiersin.org
Introduction For complete or functional cure of hepatitis B virus (HBV) infection, application
of immunotherapy is now being attempted. Recently, we reported that a 6-mer hepatitis B …

[HTML][HTML] Detection of hepatitis B virus M204V mutation quantitatively via real-time PCR

J Liang, X Liang, H Ma, L Nie, Y Tian… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Methods Blood samples were collected from patients showing viral breakthrough, primary
nonresponse, or poor response during treatment, and mutations were detected via direct …

上海市公共卫生临床中心2015—2019 年乙型肝炎病毒基因突变分析

张莉, 孟现民, 董平 - 肝脏, 2020 - hepatoday.org
目的了解上海市慢性乙型肝炎患者的HBV 耐药突变情况, 分析耐药突变的影响因素.
方法选取2015—2019 年在上海市公共卫生临床中心进行HBV 基因检测的慢性乙型肝炎 …

Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy

H Zhang, F Chen, E Giang, F Bao, GM Lauer… - Antiviral …, 2021 - journals.sagepub.com
Nucleos (t) ide analogues (NAs) are a mainstay of therapy for chronic hepatitis B (CHB)
infections and have a profound effect on hepatitis B virus (HBV) suppression. We report a …

Identification of a novel multidrug-resistance mutation in reverse transcription region of hepatitis B virus

C Rong-Juan, Y Liu, D Luo, H Bi-Xia… - Jie Fang Jun Yi Xue …, 2020 - search.proquest.com
Objective To analyze the clinical occurrence and phenotypic characteristics of rtA181S-
related novel multidrug-resistance mutation in reverse transcription region of hepatitis B …

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

J Shang, J Zhou, H Liu, RM Ise, Y Tu, J Ran… - BMC Infectious …, 2021 - Springer
Background Entecavir (ETV) is recommended as a first-line anti-HBV treatment. However,
many chronic hepatitis B patients initiate anti-HBV treatment such as lamivudine and …

替诺福韦补救治疗rtM204 位点突变的慢性乙型肝炎患者效果研究

徐文婷, 张继红, 韦冬珏, 李巍 - 实用肝脏病杂志, 2021 - manu43.magtech.com.cn
目的探讨应用替诺福韦补救治疗核苷(酸) 类经治的rtM204 位点突变的慢性乙型肝炎(CHB)
患者的效果. 方法2016 年4 月~ 2019 年2 月我院收治的94 例经阿德福韦酯或拉米夫定治疗失败 …

Antiviral drug resistance rates among patients with chronic hepatitis B infection

S Özlük, Y Bayram, A Özkaçmaz, M Parlak, A Özdemir… - 2023 - repozytorium.ur.edu.pl
Introduction and aim. Chronic hepatitis B infection (CHB) affects millions of people around
the world. Many clinicians find it challenging to choose therapeutic agents due to the …

[HTML][HTML] A Simple and Rapid Method for Quantitative Detection of Hepatitis B Virus Drug-resistant Mutations

R Wang, Z Xie - Journal of Clinical and Translational Hepatology, 2021 - ncbi.nlm.nih.gov
Hepatitis B virus (HBV) is a small-enveloped virus enclosing a partially double-stranded
DNA genome, belongs to the hepadnaviruses family. 1 To date, 10 genotypes (A–J) of HBV …